TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Symbio Pharmaceuticals Limited ( (JP:4582) ) has provided an update.
SymBio Pharmaceuticals Limited reported a significant decline in its financial performance for the first quarter of fiscal year 2025, with net sales dropping by 55.8% compared to the previous year. The company recorded substantial operating and ordinary losses, impacting its net assets and equity ratio, which decreased from the previous fiscal year. This financial downturn may affect the company’s market positioning and stakeholder confidence.
More about Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited is a company listed on the Tokyo Stock Exchange, operating in the pharmaceutical industry. It focuses on developing and commercializing innovative therapies, primarily targeting unmet medical needs in oncology, hematology, and pain management.
Average Trading Volume: 359,221
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.7B
For an in-depth examination of 4582 stock, go to TipRanks’ Stock Analysis page.